key: cord-0931089-avor9nor authors: Bronstein, Yotam; Avivi, Irit; Cohen, Yael C; Feigin, Eugene; Perry, Chava; Herishanu, Yair title: REGEN‐COV antibody combination in patients with lymphoproliferative malignancies and SARS‐CoV‐2 infection date: 2022-02-23 journal: EJHaem DOI: 10.1002/jha2.403 sha: bce02a99998fa3753684937a24a5f7eed7a27ca1 doc_id: 931089 cord_uid: avor9nor Patients with lymphoproliferative diseases are at high risk for SARS‐CoV‐2‐related complications and mortality. The role of casirivimab and imdevimab (REGEN‐COV), a neutralizing antibody cocktail, to treat immunocompromised hemato‐oncological patients with SARS‐CoV‐2 disease 2019 (Covid‐19) remains unknown. Here, we present our clinical experience on the outcome of 15 hematological patients treated with REGEN‐COV for SARS‐CoV‐2 infection. Most patients failed to respond or achieved low antibody titer after 2–3 doses of BNT162b2 mRNA vaccine. All patients experienced clinical improvement with no mortality within a median follow‐up of 70 days. In conclusion, early administration of REGEN‐COV to high‐risk hematological patients may prevent clinical deterioration and mortality from SARS‐CoV‐2 infection. The effectiveness of neutralizing antibodies may vary depending on the virus variants and in particular with the omicron variant (B.1.1.529). Patients with lymphoproliferative malignancies are at high risk of developing severe Covid-19 disease and death [1] . Several studies have shown that despite the high antibody responses to Covid-19 vaccines in the general population, responses to vaccination in patients with hematological malignancies, especially in those treated with anti-CD20 based therapies or Bruton's tyrosine kinase inhibitors (BTKis), are relatively low [2, 3] . Therefore, a key challenge is how effectively to treat immunocompromised patients with SARS-CoV-2 infection and how to prevent clinical deterioration. Casirivimab and imdevimab (REGEN-COV) is a neutralizing antibody cocktail [4] , explicitly directed against the spike protein of SARS-CoV-2. In November 2020, REGEN-COV received an emergency use authorization (EUA) from the US Food & Drug Administration (FDA) [5] This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. for the treatment of mild to moderate COVID-19 in adults and pediatric patients who are at high risk for progression to severe COVID-19, including hospitalization or death [6, 7] . However, there is a lack of data regarding the clinical efficacy of REGEN-COV in hemato-oncological patients. Herein, we report the outcome of 15 patients with hematological malignancies and SARS-CoV-2 infection treated with REGEN-COV. We conducted a retrospective, single center study of all consecutive hematological patients who were diagnosed with Covid-19 and were From July through October 2021, a total of 15 patients with hematological malignancies were included in this study (patient baseline demographic and disease characteristics are summarized in Table 1 ). The median age of the patients was 60 years (range 28-77) and 60% Patients with lymphoproliferative malignancies are at high risk of mortality from Covid-19, especially if recently treated with B-cell depleting agents [1] . Covid-19 vaccines provide immunity to some degree in patients with hematological malignancies. While patients treated with anti-CD20 antibodies, BTK-inhibitors or anti-CD38 therapy [9] , often fail to respond and are considered to be at high risk for a severe Covid-19 disease [2, 3, 10] . Here we report the outcome of 15 high-risk patients with lymphoproliferative malignancies who developed SARS-CoV-2 infection and were treated REGEN-COV. According to our findings, administration of REGEN-COV to patients, mostly presenting with mild Covid-19 disease, resulted with favorable clinical outcomes while none of the patients has clinically deteriorated (requiring high-flow oxygen, intubation, or additional Covid-19 therapy). Recent clinical studies in immunocompetent subjects suggested that anti-SARS-CoV-2 neutralizing monoclonal antibodies are particularity effective in patients with mild to moderate Covid-19 [11, 12] . Given our experience that patients with severe Covid-19 (all seronegative) have improved with REGEN-COV and none of them died, suggests that anti-SARS-CoV-2 neutralizing antibodies might have a role also in immunocompromised patients with a more severe disease. Furthermore, a recent study [13] demonstrated that among hospitalized patients with Covid-19, REGEN-COV treatment reduced 28-day mortality among patients who were seronegative in baseline. According to our local treatment protocol, anti-SARS-CoV-2 neutralizing antibody cocktails are given early, up to 10 days, after the development of symptoms, aiming to prevent clinical deterioration. Nevertheless, in immunocompromised patients, especially in those treated with anti-CD20 antibodies, our local protocol allows treatment with REGEN-COV after more than 10 days from onset of symptoms, after consulting with an infectious disease specialist. Accordingly, two patients received REGEN-COV after more than 10 days (range 11- IA, YH, YC, EF, and CP provided clinical data for the patients. YB and IA wrote the manuscript. YH revised the manuscript. All authors reviewed and commented on the revised manuscript before submission. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies Effectiveness of the BNT162b2mRNA Covid-19 vaccine in patients with hematological neoplasms REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19 COVID-19) update: FDA authorizes monoclonal antibodies for treatment of COVID-19 Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19 REGEN-COV antibody combination and outcomes in outpatients with Covid-19 Israeli ministry of health protocol for COVID-19 disease severity Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer New analyses of two AZD7442 COVID-19 Phase III trials in high-risk populations confirm robust efficacy and long-term prevention. Novemeber 18 Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19 Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet REGEN-COV antibody combination in patients with lymphoproliferative malignancies and SARS-CoV-2 infection The authors have no competing interests. Yotam Bronstein https://orcid.org/0000-0002-3026-8724Yael C Cohen https://orcid.org/0000-0002-9061-7287